Document:

Filed by Automated Filing Services Inc. (604) 609-0244 - Response Biomedical Corp. - Exhibit 4.12

 WITHOUT PRIOR WRITTEN APPROVAL OF THE EXCHANGE AND COMPLIANCE
  WITH ALL APPLICABLE SECURITIES LEGISLATION, THE SECURITIES REPRESENTED BY THIS
  CERTIFICATE MAY NOT BE SOLD, TRANSFERRED, HYPOTHECATED OR OTHERWISE TRADED ON
  OR THROUGH THE FACILITIES OF THE TSX VENTURE EXCHANGE OR OTHERWISE IN CANADA
  OR TO OR FOR THE BENEFIT OF A CANADIAN RESIDENT UNTIL _________.
  

 UNLESS PERMITTED UNDER SECURITIES LEGISLATION, THE HOLDER
  OF THE SECURITIES SHALL NOT TRADE THE SECURITIES BEFORE ________.
  

 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED
  UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "U.S. SECURITIES
  ACT") OR ANY STATE SECURITIES LAWS. THE HOLDER HEREOF, BY PURCHASING SUCH SECURITIES,
  AGREES FOR THE BENEFIT OF THE COMPANY THAT SUCH SECURITIES MAY BE OFFERED, SOLD
  OR OTHERWISE TRANSFERRED ONLY (A) TO THE COMPANY, (B) IF OUTSIDE THE UNITED
  STATES, IN AN OFFSHORE TRANSACTION IN COMPLIANCE WITH RULE 904 OF REGULATION
  S UNDER THE U.S. SECURITIES ACT AND IN COMPLIANCE WITH APPLICABLE LOCAL LAWS
  AND REGULATIONS, OR (C) IF WITHIN THE UNITED STATES, EITHER (1) PURSUANT TO
  AN AVAILABLE EXEMPTION UNDER THE U.S. SECURITIES ACT AND ANY APPLICABLE STATE
  SECURITIES LAWS, UPON RECEIPT BY THE COMPANY OF A LEGAL OPINION (IN FORM AND
  SUBSTANCE SATISFACTORY TO THE COMPANY) TO SUCH EFFECT, OR (2) PURSUANT TO AN
  EFFECTIVE REGISTRATION STATEMENT UNDER THE U.S. SECURITIES ACT FOR SUCH SECURITIES.
  DELIVERY OF THIS CERTIFICATE MAY NOT CONSTITUTE GOOD DELIVERY IN SETTLEMENT
  OF TRANSACTIONS ON STOCK EXCHANGES IN CANADA. A NEW CERTIFICATE BEARING NO LEGEND
  MAY BE OBTAINED FROM THE COMPANY'S REGISTRAR AND TRANSFER AGENT UPON DELIVERY
  OF THIS CERTIFICATE AND A DULY AUTHORIZED DECLARATION, IN A FORM SATISFACTORY
  TO THE REGISTRAR AND TRANSFER AGENT AND THE COMPANY, TO THE EFFECT THAT SUCH
  SALE IS BEING MADE IN ACCORDANCE WITH RULE 904 OF REGULATION S UNDER THE U.S.
  SECURITIES ACT. 

CERTIFICATE #________ 

REPRESENTING ________ WARRANTS 

 NON-TRANSFERABLE SHARE PURCHASE WARRANT

 RESPONSE BIOMEDICAL CORP. 

 (Incorporated under the laws of the Province of British Columbia)

 This is to certify that, for value received, ________
  (the “Warrant Holder”) of «Address», has the right to
  purchase from Response Biomedical Corp. (the “Company”),
  upon and subject to the terms and conditions hereinafter referred to, ________common
  shares without par value (the “Shares”) in the capital of the Company.
  The Shares may be purchased at the price of ________ per Share (the “Exercise
  Price”) at any time prior to 4:30 p.m. (local Vancouver time) on ________subject
  to the terms and conditions hereinafter set forth. The right to purchase the
  Shares may be exercised in whole or in part, by the Warrant Holder only, at
  the Exercise Price by 4:30 p.m. on ________ by: 

	 	 (a)      	 completing and executing the form (the “Subscription
        Form”) attached hereto for the number of the Shares which the Warrant
        Holder wishes to purchase, in the manner therein indicated; 

	 
	 	 (b)      	 surrendering this Warrant Certificate, together
        with the complete Subscription Form, to Computershare Investor Services,
        Inc., 510 Burrard Street, Vancouver, BC, V6C 3B9; and 

	 
	 	 (c)      	 paying the appropriate Exercise Price, in Canadian
        funds, for the number of the Shares of the Company subscribed for, either
        by certified cheque or bank draft (drawn on a 

 – 2 – 

	 	 	Canadian Chartered Bank) or money order payable to
        the Company in Vancouver, British Columbia. 

      

Upon surrender and payment, the Company shall issue to the
  Warrant Holder or to such other person or persons as the Warrant Holder may
  direct, the number of the Shares subscribed for and will deliver to the Warrant
  Holder, at the address set forth on the subscription form, a certificate or
  certificates evidencing the number of the Shares subscribed for within a reasonable
  time, not exceeding 7 days after the rights represented by this Warrant Certificate
  shall have been exercised. If the Warrant Holder subscribes for a number of
  Shares which is less than the number of Shares permitted by this Warrant, the
  Company shall forthwith cause to be delivered to the Warrant Holder a further
  Warrant Certificate in respect of the balance of Shares referred to in this
  Warrant Certificate not then being subscribed for. 

 The Company covenants and agrees that all Shares which may
  be issued upon the exercise of this Warrant will, upon issuance, be fully paid
  and non-assessable and free of all liens, charges and encumbrances. The Company
  further covenants and agrees that during the period within which the rights
  represented by this Warrant Certificate may be exercised, the Company will at
  all times have authorized and reserved a sufficient number of Shares to provide
  for the exercise of this Warrant represented by this Warrant Certificate. 

 Anti-Dilution

 The Exercise Price and the number of Shares deliverable upon
  the exercise of these Warrants will be subject to adjustment in the events and
  in the following manner: 

	 (a)      	 In case of any reclassification of the common shares
        or change of the common shares into other shares, or in case of the consolidation,
        merger, reorganization or amalgamation of the Company with or into any
        other corporation or entity which results in any reclassification of the
        common shares or a change of the common shares into other shares, or in
        case of any transfer, lease or license of the undertaking or assets of
        the Company as an entirety or substantially as an entirety to another
        person (any such event being hereinafter referred to as a “Reclassification
        of Common Shares”), at any time prior to the Time of Expiry, the
        Warrant Holder shall, after the effective date of such Reclassification
        of Common Shares and upon exercise of the right to purchase Shares hereunder,
        be entitled to receive, and shall accept, in lieu of the number of Shares
        to which the Warrant Holder was theretofore entitled upon such exercise,
        the kind and amount of shares and other securities or property which the
        Warrant Holder would have been entitled to receive as a result of such
        Reclassification of Common Shares if, on the effective date thereof, the
        Warrant Holder had been the registered holder of the number of Shares
        to which the Warrant Holder was theretofore entitled upon such exercise.
        If necessary, appropriate adjustments shall be made in the application
        of the provisions set forth in this section with respect to the rights
        and interests thereafter of the Warrant Holder of this Warrant Certificate
        to the end that the provisions set forth in this section shall thereafter
        correspondingly be made applicable as nearly as may be reasonable in relation
        to any shares or other securities or property thereafter deliverable upon
        the exercise of the Warrants evidenced hereby. 

	 
	 (b)      	 If and whenever at any time prior the Time of Expiry
        the Company shall: 

	 	(i) 	subdivide its common shares into a greater number
        of shares; 

	 	 	 
	 	(ii) 	consolidate its common shares into a lesser number
        of shares; or 

 – 3 – 

	 	 (iii)   
          
	 issue common shares, Participating Shares or Convertible
        Securities (both such terms as defined below in paragraph (g)) to all
        or substantially all of the holders of common shares by way of a stock
        dividend or other distribution on the common shares payable in common
        shares, Participating Shares or Convertible Securities; 

	 
	 	 (any such event being hereinafter referred
        to as “Capital Reorganization”) and any such event results
        in an adjustment in the Exercise Price hereunder, the number of Shares
        purchasable pursuant to the Warrants evidenced hereby shall be adjusted
        contemporaneously with the adjustment of the Exercise Price by multiplying
        the number of Shares theretofore purchasable on the exercise thereof by
        a fraction the numerator of which shall be the Exercise Price in effect
        immediately prior to such adjustment and the denominator of which shall
        be the Exercise Price resulting from such adjustment. 

	 
	 (c)      	 If and whenever at any time prior to the
        Time of Expiry, the Company shall engage in a Capital Reorganization,
        the Exercise Price shall, on the effective date, in the case of a subdivision
        or consolidation, or on the record date, in the case of a stock dividend,
        be adjusted by multiplying the Exercise Price in effect on such effective
        date or record date by a fraction: (A) the numerator of which shall be
        the number of common shares and Participating Shares outstanding before
        giving effect to such Capital Reorganization; and (B) the denominator
        of which is the number of common shares and Participating Shares outstanding
        after giving effect to such Capital Reorganization. The number of common
        shares and Participating Shares outstanding shall include the deemed conversion
        into or exchange for common shares or Participating Shares of any Convertible
        Securities distributed by way of stock dividend or other such distribution.
        Such adjustment shall be made successively whenever any event referred
        to in this paragraph shall occur. 

	 
	 (d)      	 Any issue of common shares, Participating
        Shares or Convertible Securities by way of a stock dividend or other such
        distribution shall be deemed to have been made on the record date thereof
        for the purpose of calculating the number of outstanding common shares
        under paragraphs (e) and (f) 

	 
	 (e)      	 If and whenever at any time prior to the
        Time of Expiry, the Company shall fix a record date for the issuance of
        rights, options or warrants (other than the Warrants evidenced hereby)
        to all or substantially all the holders of common shares entitling them,
        for a period expiring not more than 45 days after such record date, to
        subscribe for or purchase common shares, Participating Shares or Convertible
        Securities at a price per share (or having a conversion or exchange price
        per share) of less than 95% of the Current Market Price (as defined below)
        of the common shares on such record date (any such event being hereinafter
        referred to as a “Rights Offering”), the Exercise Price shall
        be adjusted immediately after such record date so that it shall equal
        the price determined by multiplying the Exercise Price in effect on such
        record date by a fraction: 

	 
	 	 (i)      
	 the numerator of which shall be the aggregate of:
        (A) the number of common shares outstanding on such record date; and (B)
        a number determined by dividing whichever of the following is applicable
        by the Current Market Price of the common shares on the record date: (1)
        the amount obtained by multiplying the number of common shares or Participating
        Shares which the holders of common shares are entitled to subscribe for
        or purchase by the subscription or purchase price; or (2) the amount obtained
        by multiplying the maximum number of common shares or Participating Shares
        which the holders of common shares are entitled to receive on the conversion
        or exchange of the Convertible Securities by the conversion or exchange
        price per share; and 

 – 4 – 

	 	 (ii)     
      
	 the denominator of which shall be the aggregate
        of: (A) the number of common shares outstanding on such record date; and
        (B) whichever of the following is applicable: (1) the number of common
        shares or Participating Shares which the holders of common shares are
        entitled to subscribe for or purchase; or (2) the maximum number of common
        shares or Participating Shares which the holders of common shares are
        entitled to receive on the conversion or exchange of the Convertible Securities.
      

	 
	 	
Any common shares owned by or held for the account
        of the Company shall be deemed not to be outstanding for the purpose of
        any such computation. Such adjustment shall be made successively whenever
        such a record date is fixed. 

	 
	 	
To the extent that such Rights Offering is not so made
        or any such rights, options or warrants are not exercised prior to the
        expiration thereof, the Exercise Price shall then be readjusted to the
        Exercise Price which would then be in effect if such record date had not
        been fixed or if such expired rights, options or warrants had not been
        issued. 

	 
	 (f)      	 If and whenever at any time prior to the
        Time of Expiry, the Company shall fix a record date for the distribution
        to all or substantially all the holders of common shares of: 

	 
	 	 (i)      
	 shares of any class, whether of the Company or any
        other corporation; 

	 
	 	 (ii)      
	 rights, options or warrants; 

	 
	 	 (iii)      
	 evidences of indebtedness; or 

	 
	 	 (iv)      
	 other assets or property; 

	 
	 	
and if such distribution does not constitute a Capital
        Reorganization or a Rights Offering or does not consist of rights, options
        or warrants entitling the holders of common shares to subscribe for or
        purchase common shares, Participating Shares or Convertible Securities
        for a period expiring not more than 45 days after such record date and
        at a price per share (or having a conversion or exchange price per share)
        of at least 95% of the Current Market Price of the common shares on such
        record date (any such non-excluded event being hereinafter referred to
        as a “Special Distribution”) the Exercise Price shall be adjusted
        immediately after such record date so that it shall equal the price determined
        by multiplying the Exercise Price in effect on such record date by a fraction:
        (I) the numerator of which shall be the amount by which (A) the amount
        obtained by multiplying the number of common shares outstanding on such
        record date by the Current Market Price of the common shares on such record
        date, exceeds (B) the fair market value (as determined by the directors
        of the Company, which determination shall be conclusive) to the holders
        of such common shares of such Special Distribution; and (II) the denominator
        of which shall be the total number of common shares outstanding on such
        record date multiplied by such Current Market Price. 

	 
	 	 Any common shares owned by or held for
        the account of the Company shall be deemed not to be outstanding for the
        purpose of any such computation. Such adjustment shall be made successively
        whenever such a record date is fixed. 

	 
	 	 To the extent that such Special Distribution
        is not so made or any such rights, options or warrants are not exercised
        prior to the expiration thereof, the Exercise Price shall then be readjusted
        to the Exercise Price which would then be in effect if such record date
        had not been fixed or if such expired rights, options or warrants had
        not been issued. 

 – 5 – 

	 (g)      	 For the purpose of these Warrants: (i) “Participating
        Share” means a share (other than a common share) that carries the
        right to participate in earnings to an unlimited degree; and (ii) “Convertible
        Security” means a security convertible into or exchangeable for
        a common share or a Participating Share or both. 

	 
	 (h)      	 In any case in which this Warrant Certificate shall
        require that an adjustment shall become effective immediately after a
        record date for an event referred to herein, the Company may defer, until
        the occurrence of such event, issuing to the Warrant Holder, upon the
        exercise of the Warrants evidenced hereby after such record date and before
        the occurrence of such event, the additional Shares issuable upon such
        exercise by reason of the adjustment required by such event; provided,
        however, that the Company shall deliver to the Warrant Holder an appropriate
        instrument evidencing the Warrant Holder’s right to receive such
        additional Shares upon the occurrence of the event requiring such adjustment
        and the right to receive any distributions made on such additional Shares
        on and after such exercise. 

	 
	 (i)      	 The adjustments provided for in this Warrant Certificate
        are cumulative, shall, in the case of adjustments to the Exercise Price,
        be computed to the nearest one-tenth of one cent and shall apply (without
        duplication) to successive Reclassifications of Common Shares, Capital
        Reorganizations, Rights Offerings and Special Distributions; provided
        that, notwithstanding any other provision of this section, no adjustment
        of the Exercise Price shall be required unless such adjustment would require
        an increase or decrease of at least 1% of the Exercise Price then in effect
        (except upon a consolidation of the outstanding common shares) (provided,
        however, that any adjustments which by reason of this paragraph are not
        required to be made shall be carried forward and taken into account in
        any subsequent adjustment). 

	 
	 (j)      	 In the event of any question arising with respect
        to the adjustments provided in this Warrant Certificate, such question
        shall conclusively be determined by a firm of chartered accountants appointed
        by the Company (who may be the Company’s auditors). The Company
        shall give such accountants access to all necessary records of the Company
        and such determination shall be binding upon the Company and the Warrant
        Holder. 

	 
	 (k)      	 As a condition precedent to the taking of any action
        which would require an adjustment in the subscription rights pursuant
        to these Warrants, including the Exercise Price and the number of such
        classes of shares or other securities or property which are to be received
        upon the exercise thereof, the Company shall take all corporate action
        which may, in the opinion of counsel, be necessary in order that the Company
        has reserved and there will remain unissued out of its authorized capital
        a sufficient number of Shares for issuance upon the exercise of these
        Warrants, and that the Company may validly and legally issue as fully
        paid and non-assessable all the shares of such classes or other securities
        or may validly and legally distribute the property which the Warrant Holder
        is entitled to receive on the full exercise thereof in accordance with
        the provisions hereof. 

	 
	 (l)      	 At least 15 days prior to the effective date or
        record date, as the case may be, of any dividend of any kind or any event
        which requires an adjustment in the subscription rights pursuant to this
        Warrant Certificate, including the Exercise Price and the number and classes
        of shares or other securities or property which are to be received upon
        the exercise thereof, the Company shall give notice to the Warrant Holder
        of the particulars of such event and the required adjustment. Upon the
        occurrence of any event which requires any adjustment of the Exercise
        Price or number of Shares, then, and in each such case, the Company shall
        give notice thereof to the holder hereof, which notice shall state the
        Exercise Price resulting from such adjustment and the increase or decrease
        in the number of Shares purchasable at such price upon exercise, setting
        forth in 

 – 6 – 

	 	 reasonable detail the method of calculation and
        the facts upon which such calculation is based. Such calculation shall
        be certified by the Chief Financial Officer of the Company. 

	 
	 (m)      	 No adjustment in the number of Shares which may
        be purchased upon exercise of the Warrants evidenced hereby or in the
        Exercise Price shall be made pursuant to this Warrant Certificate if the
        Warrant Holder is entitled to participate in such event on the same terms
        mutatis mutandis as if the Warrant Holder had exercised the Warrants evidenced
        hereby for Shares prior to the effective date or record date of such event.
      

 The Company shall not be required to issue Shares upon the
  exercise of these Warrants or provide any compensation in lieu of such fractional
  interests, if any. 

 Current Market Price

 The Current Market Price of the common shares at any date
  shall be determined as follows: 

	 (a)      	 if the common shares are quoted on the TSX Venture
        Exchange, the Current Market Price of a common share will be the weighted
        average closing price of the common shares on such exchange for the 20
        prior trading days; 

	 
	 (b)      	 if the common shares are not quoted on the TSX Venture
        Exchange but are listed and posted for trading on another recognized stock
        exchange or trading quotation system, the Current Market Price of a common
        share will be the weighted average closing price for the 20 prior trading
        days of the common shares on such exchange or system or if such exchange
        or system does not provide a closing price, the numerical average of the
        closing bid and ask prices of the common shares, in either case, for the
        20 prior trading days; and 

	 
	 (c)      	 if the common shares are not so listed and traded,
        the Board of Directors of the Company shall forthwith and in good faith
        determine the fair market value of a common share as of such date. 

 The holding of this Warrant Certificate or the Warrants represented
  hereby does not entitle the Warrant Holder a to any rights as shareholder of
  the Company. 

 Nothing contained herein confers any right upon the Warrant
  Holder or any other person to subscribe for or purchase any Shares of the Company
  at any time subsequent to 4:30 p.m. local time in Vancouver, B.C. on ________
  and from and after such time, this Warrant and all rights hereunder will
  be void. 

 The Warrants represented by this Warrant Certificate are non-transferable.
  Any Shares issued pursuant to this Warrant prior to ________ will bear
  the following legends: 

“WITHOUT PRIOR WRITTEN APPROVAL
  OF THE EXCHANGE AND COMPLIANCE WITH ALL APPLICABLE SECURITIES LEGISLATION, THE
  SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE SOLD, TRANSFERRED, HYPOTHECATED
  OR OTHERWISE TRADED ON OR THROUGH THE FACILITIES OF THE TSX VENTURE EXCHANGE
  OR OTHERWISE IN CANADA OR TO OR FOR THE BENEFIT OF A CANADIAN RESIDENT UNTIL
  ________ .

“UNLESS PERMITTED UNDER
  SECURITIES LEGISLATION, THE HOLDER OF THE SECURITIES SHALL NOT TRADE THE SECURITIES
  BEFORE ________.”Time will be of the essence
  hereof. 

 This Warrant Certificate is not valid for any purpose until
  it has been signed by the Company. 

 – 7 – 

 IN WITNESS WHEREOF, the Company has caused its common seal
  to be hereto affixed and this Warrant Certificate to be signed by any one of
  the directors of the Company as of the _____ day of ________. 

	RESPONSE BIOMEDICAL CORP. 	 
	 	 
	 	 
	 	 
	Per: 	 

 SUBSCRIPTION FORM

	
To: 
		
Response Biomedical Corp. (the “Company”) 
	
	
And to: 
		
the directors thereof. 
	

 Pursuant to the Share Purchase Warrant made the _____ of ________
  , 200_ the undersigned hereby subscribes for and agrees to take up _______________
  common shares without par value (the “Shares”) in the capital of
  the Company, at a price of $  (Canadian) per Share for the aggregate
  sum of $ _______________ (the “Subscription Funds”), and encloses
  herewith a certified cheque, bank draft or money order payable to the Company
  in full payment of the Shares. 

 The undersigned (the “Subscriber”) hereby requests
  that upon receipt of the Subscription Funds by the Company: 

	 	 (a)      	 the Shares be allotted to the person set out under
        the registration directions shown below; 

	 
	 	 (b)      	 the name and address of the person set out under
        the registration directions shown below be entered in the registers of
        members and allotments of the Company; 

	 
	 	 (c)      	 the Shares be issued to the person set out under
        the registration directions shown as fully paid and non-assessable common
        shares of the Company; and 

	 
	 	 (d)      	 a share certificate representing the Shares be registered
        in accordance with the registration directions shown below. 

 Dated this _______ day of ______________ , 20[___]. 

 DIRECTION AS TO REGISTRATION: 

 (Name and address exactly as you wish
  them to appear on the share certificate representing the Shares and in the register
  of members.) 

	 Full Name(1):  	 
	 	 
	 Full Address:  	 
	  	 
	  	 
	 	 
	 	 
	 	 
	 Signature of Subscriber(1):  	 

	 (1)If the name above differs from the
      name of the Subscriber, 

      then please complete the following guarantee:  	 Signature of Subscriber guaranteed by:  

      
 
 
 ________________________________________________
 Authorized
      Signature Number  

 NOTE: The signature to this Subscription Form must
  correspond with the name as recorded on the Warrant Certificate accompanying
  this Subscription Form in every particular without alteration or enlargement
  or any change whatever. If not, the signature of the person executing this power
  must be guaranteed by a Bank or Trust Company or by a Member of the TSX Venture,
  TSX, or New York Stock Exchange.Filed by Automated Filing Services Inc. (604) 609-0244 - Response Biomedical Corp. - Exhibit 4.14

 

		 
	  TD Tower Branch  	  
	  Commercial Banking Centre  	  
	  2nd Floor, TD Tower  	  
	  700 Georgia Street W., Pacific Centre 
    	  
	  PO Box 10001  	  
	 Vancouver, BC V7Y 1A2  	  
	  	 
	  	 Telephone No. : (604) 654-3554  
	  	 Fax No. : (604) 654-3489  

 December 13, 2004 

 Response Biomedical Corp.

  8081 Lougheed Hwy 

  Burnaby, B.C. 

  V5A 1W9 

 Attn: Mr. Bill Radvak and Mr. Robert Pilz, 

 Dear Sirs, 

 DEMAND OPERATING FACILITY AGREEMENT AMENDMENT 

	 This Amending  	  
	 Agreement between:  	 The Toronto-Dominion Bank (the "Bank"),
      through its branch, in 
	 	 
	  	and  
	 	 
	 Borrower's Legal Name:  	  (herein called the "Borrower")  
	 	 
	 Borrower's Address:  	  
	 	 
	 Whereas:  	 The Bank has agreed to establish a revolving
      demand credit facility (the "Facility") as per the Demand Operating Facility
      Agreement dated June 16, 2004 which together with Schedule "A" of the Demand
      Operating Facility Agreement comprise the "Agreement".

 In consideration of the Bank continuing to make the Facility available, the
  Borrower hereby agrees with the Bank to the following amendments to the terms
  and conditions of the Agreement: 

	 AVAILABILITY  	  
	 OF THE FACILITY 
    	 The Borrower acknowledges that the Facility is uncommitted
      and is not automatically available upon satisfaction of the terms and conditions,
      including without limitation the Representations & Warranties, Positive
      Covenants, Negative Covenants, or Financial Covenants set out herein.
	  	 
	  	 The Bank can demand repayment and/or cancel the availability
      of the Facility at any time.  

 

	 REPAYMENT  	 The Borrower agrees to repay the
      Bank on demand. If the Bank demands repayment, the Borrower will pay to
      the Bank all amounts outstanding under the Facility, including without limitation,
      as applicable, the amount of all unmatured B/As and the amount of all drawn
      and undrawn L/Gs and L/Cs. All costs to the Bank and all loss suffered by
      the Bank in re-employing the amounts so repaid will be paid by the Borrower.
    
	  	 	 
	  	 In absence of prior demand, Facility
      #1 is to be repaid in full on or before December 15, 2005.  
	  	 	 
	 SECURITY  	 The Borrower will provide the following
      additional security to support all of its present and future indebtedness
      and liability to the Bank including without limitation indebtedness and
      liability under guarantees, foreign exchange contracts, cash management
      products, and derivative contracts:
	  	 	 Irrevocable Standby Letter of Credit - US$1,000,000 issued
      by Bank Sarasin of Basel Switzerland  in favour of TD Bank, Global
      Trade Finance and Financial Institutions, expiring December 30,  2005. 
    
	  	 	 
	  	 All persons and entities required
      to provide a guarantee shall be referred to herein individually as a "Guarantor"
      and/or "Surety" and collectively as the "Guarantors". All of the above security
      and guarantees and any previously provided Bank Security shall be referred
      to collectively in this Agreement as "Bank Security". The security will
      be registered in first position, and will be on the Bank's standard form,
      supported by resolutions and solicitor's opinion, all acceptable to the
      Bank.
	  	 	 
	  	 	 
	 SCHEDULE "A"  	 	  
	 TERMS AND  	 	  
	 CONDITIONS  	 Schedule "A" sets out the Standard
      Terms and Conditions ("Standard Terms and Conditions") which are applicable
      to the Borrower and which apply to this Facility. The Standard Terms and
      Conditions, including the defined terms set out therein, form part of this
      Agreement, unless this letter states specifically that one or more of the
      Standard Terms and Conditions do not apply or are modified.

 Unless otherwise stated, the amendments outlined above are in addition to
  the Terms and Conditions of the existing Agreement. All other terms and conditions
  remain unchanged. We ask that you acknowledge your agreement to these amendments
  by signing and returning the attached duplicate copy of this Amending Agreement
  to the undersigned. The amendments will not come into force unless the duplicate
  of this Amending Agreement is received by the Bank on or before December
  22, 2004. 

 Yours truly, 

 THE TORONTO-DOMINION BANK 

	 /s/ JOEL WHITTEMORE  	 /s/ ALIX ROSS  
	 Joel Whittemore  	 Alix Ross  
	 Relationship Manager  	 Manager, Commercial Credit  

 The foregoing is acknowledged and accepted by the Borrower. The following
  persons have the capacity to bind the Borrower. 

 Borrower's authorized officers or representatives: 

	 /s/ ROBERT PILZ  	 /s/ BRIAN RICHARDS  
	 Signature  	 Signature  
	  	 
	  	 
	 ROBERT PILZ, cfo  	 BRIAN RICHARDS, EXECUTIVE VP, DIRECTOR  
	 Print Name & Position  	 Print Name & Position  
	  	 
	  	 
	 DEC.13, 2004  	 13-12-04  
	 Date:  	 Date:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00083-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00083-of-00352.parquet"}]]